Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for liver cancer patients when first treatments stop working

NCT ID NCT07219459

Summary

This study is testing whether adding an experimental drug called visugromab to standard cancer medications works better for people with advanced liver cancer. It's for patients whose first treatment that included immunotherapy has stopped controlling their cancer. Researchers will compare the new combination against standard treatment to see if it helps control cancer growth longer and improves survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.